Metformin

glucagon like peptide 1 receptor ; Homo sapiens







77 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
51 26480253 [Anti-diabetics and chronic kidney disease]. 2015 Sep-Oct 1
52 26487791 Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin. 2015 Oct 1
53 23668534 Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. 2014 Feb 1
54 24106875 Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. 2014 Mar 1
55 24233023 Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. 2014 Feb 1
56 24918793 Evidence-based practice use of incretin-based therapy in the natural history of diabetes. 2014 May 1
57 25089625 Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. 2014 2
58 25172519 Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity? 2014 Oct 2
59 25568561 Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia. 2014 Oct 1
60 22850868 Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. 2013 Mar 4
61 23831441 Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. 2013 Sep 1
62 23955995 The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes. 2013 Nov 1
63 23971789 Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes. 2013 Dec 1
64 24321717 Effects of aerobic exercise with or without metformin on plasma incretins in type 2 diabetes. 2013 Dec 2
65 22432846 GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. 2012 Aug 1
66 22982676 Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells. 2012 Oct 12 1
67 21205107 Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. 2011 Mar 1
68 21517658 Liraglutide: a review of the first once-daily GLP-1 receptor agonist. 2011 Mar 1
69 21971158 Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. 2011 Dec 5
70 20722676 Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. 2010 Sep 1
71 20868233 Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells. 2010 Dec 1
72 19318378 Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. 2009 Jun 1
73 19385979 The scientific evidence: vildagliptin and the benefits of islet enhancement. 2009 May 2
74 19744424 Practical applications of therapy with a glucagon-like peptide-1 receptor agonist. 2009 Sep 1
75 17342635 [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus]. 2007 Mar 16 1
76 18217246 Clinical management strategies for type 2 diabetes. 2007 Dec 1
77 16987706 GLP-1 and type 2 diabetes: physiology and new clinical advances. 2006 Dec 1